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ABSTRACT
Background The endurance shuttle walking test (ESWT)
has shown good responsiveness to interventions in
patients with chronic obstructive pulmonary disease
(COPD). However, the minimal important difference
(MID) for this test remains unknown, therefore limiting
its interpretability.
Methods Patients with COPD who completed two or
more ESWTs following pulmonary rehabilitation
(n¼132; forced expiratory volume in 1 s (FEV1)
48622%) or bronchodilation (n¼69; FEV1 50612%)
rated their performance of the day in comparison with
their previous performance on a 7-point scale ranging
from 3 (large deterioration) to +3 (large
improvement). The relationship between subjective
perception of changes and objective changes in
performance during the shuttle walk was evaluated.
Results Following pulmonary rehabilitation, the anchor-
based approach did not allow a valid estimation of the
MID in the ESWT performance to be obtained. After
bronchodilation, patient ratings of change correlated
significantly with the difference in walking distance
(r¼0.53, p<0.001) and endurance time (r¼0.55,
p<0.001). For the pharmacotherapy data, regression
analysis indicated that a 65 s (95% CI 45 to 85) change
in endurance time and a 95 m (95% CI 60 to 115)
change in walking distance were associated with a
1-point change in the rating of change scale. These
changes represented 13e15% of the baseline values.
Conclusions A change in endurance shuttle walking
performance of 45e85 s (or 60e115 m) after
bronchodilation is likely to be perceived by patients. This
MID value may be specific to the intervention from which
it was derived.
INTRODUCTION
Exercise testing has become a key approach to
evaluate the functional impact of chronic obstruc-
tive pulmonary disease (COPD) treatments
because it allows the assessment of exercise toler-
ance and exertional dyspnoea, two fundamental
outcomes in patients with COPD.1 While maximal
progressive cycle ergometry remains the most
widely used exercise test in clinical practice,1
constant-load tests have gained popularity in
recent years because of their enhanced sensitivity
to various interventions.2e9
The endurance shuttle walking test (ESWT), an
externally paced constant-speed ﬁeld walking test,
has shown high responsiveness to treatment in
patients with COPD.10e13 In a randomised, double-
blind, placebo-controlled and crossover trial, the
ESWT was found to capture larger and more
consistent improvements in exercise performance
after the administration of ipratropium bromide
compared with a constant-load cycling exercise test
performed at 80% of peak work rate.11
Based on the evidence accumulated to date, the
ESWTseems particularly suited to detect functional
improvements after treatment in patients with
COPD. Furthermore, like other ﬁeld tests, the
ESWT has the advantage of requiring minimal
equipment and less technical expertise than labo-
ratory-based tests, thereby being less expensive and
easier to administer.5 It is also perceived as being
more reﬂective of daily living than laboratory-based
tests (because it employs a daily living activity; ie,
walking on a ﬂat surface) and yet being more
standardised than self-paced walking tests (eg, the
6 minute walk test (6-MWT)) because it imposes
the walking speed and is thereby less affected by
patient motivation and pacing ability.5 14
However, the minimal important difference
(MID) for the ESWT has yet to be established,
limiting the interpretability of observed changes in
performances. The MID corresponds to the
smallest change that can be perceived by patients.15
By providing an indicator of the amplitude of
change needed for patients to detect a signiﬁcant
difference in a given outcome variable, the MID
allows clinicians and researchers to interpret ﬁnd-
ings from clinical trials beyond their statistical
signiﬁcance by considering clinical meaningfulness.
While there are many acknowledged methods to
estimate the MID, there is no consensus on which
method is to be favoured. However, it is recognised
that using multiple methods to triangulate the
MID is a valid path.16
The present study was undertaken to determine,
in patients with COPD, the MID for the ESWT.
Speciﬁcally, our objectives were to use data from
both pulmonary rehabilitation and bronchodilation
studies to: (1) evaluate the degree of association
between objective and subjective measures of
changes in ESWT performance after these inter-
ventions; and (2) provide an estimate of the MID
for the ESWT. We hypothesised that we would be
able to determine an MID value for the ESWT from
bronchodilation and pulmonary rehabilitation
studies. Some of the results of this study have been
reported previously in the form of an abstract.17
METHODS
Settings
Data were obtained from two distinct settings:
pulmonary rehabilitation studies from Leicester
and Nottinghamshire, UK; and bronchodilation
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studies from the Institut Universitaire de cardiologie et de
pneumologie de Québec, Canada.
Rehabilitation data were collected from two separate cohorts
of patients with COPD that underwent pulmonary rehabilita-
tion. Participants from both cohorts participated in a 7 week
programme which included aerobic and resistance exercises,
three times per week.18 Participants completed two ESWTs, one
at baseline and one after the rehabilitation programme,
amounting to one comparison point per participant. A total of
132 patients were included in the two programmes, resulting in
132 comparison points.
Bronchodilation studies were conducted as part of a clinical
research programme seeking to evaluate the responsiveness of
the ESWT to detect improvements in exercise capacity following
bronchodilation in patients with COPD. This programme was
also initially set up to estimate the MID of the ESWT. While the
data pertaining to the ESWT’s responsiveness to bronchodila-
tion have been published,11 19 20 none of the MID data has been
reported, except in the form of an abstract.17 Study participants
completed between two and four ESWTs as part of these trials,
such that the number of comparison points obtained per
participant varied from one to three. From a total of 69 patients,
146 comparison points were thus obtained. These studies used
a randomised double-blind controlled crossover methodology.
Because the order of drug administration was randomised, the
second ESWT of any comparison pair could be done under
placebo or bronchodilation conditions. As a result of this study
design, deterioration, status quo or improvement could be
perceived after the second test of a pair in comparison with the
ﬁrst test. The time between two ESWTs of the same pair varied
from 2 to 14 days. The detailed methodology for these trials has
been reported previously.11 19 20
Endurance shuttle walking test
The ESWTwas performed in an enclosed corridor on a ﬂat 10 m
long course, following the procedure described by Revill and
colleagues.10 After a 90 s warm-up, walking speed was set at the
pace corresponding to 80e85% of VO2 peak, which was esti-
mated from the distance walked during a previously completed
incremental shuttle walking test (ISWT).21 Before each test,
participants were instructed to walk for as long as possible at
the speed dictated by the auditory signal. The endurance time as
well as the distance covered in that time were recorded. The
warm-up period was excluded from this analysis.
Global rating of change
Immediately after each ESWT (with the exception of the initial
one) and before any feedback was given about the test’s result,
participants were asked the following question: ‘In comparison
with your previous test, how would you rate your performance
on today’s test using the present scale?’ Patients rated their
performance on a 7-point Likert scale. The scale ranged from 3
to +3 and included the following ratings: 3 (large deteriora-
tion), 2 (moderate deterioration), 1 (slight deterioration),
0 (no change), 1 (slight improvement), 2 (moderate improve-
ment) and 3 (large improvement).15 22
Statistical analyses
The absolute (delta) and relative (%) difference between
consecutive ESWT performances (expressed in both seconds and
metres) was computed for each participant. The degree of
association between the objective measures of change in ESWT
performance and the participant’s ratings of that change was
assessed with Pearson correlations. The MID was then estimated
using both distribution- and anchor-based approaches. For the
distribution-based method, the MID was calculated as half the
SD of the changes in ESWT endurance time and distance.23
For the anchor-based approach, we investigated the statistical
relationship between the patient’s rating of change and
improvements in ESWT performance using models. First,
Pearson correlations between participant rating and changes in
ESWT endurance time or distance needed to be $0.5 to obtain
valid regression equations.24 If this condition was fulﬁlled,
participant rating of change (independent variable) from
each intervention group was plotted in a linear regression model
against the absolute or relative (% baseline value) change in
ESWT performance. The resulting slopes, which represented the
change needed in walking time or distance for participants’
ratings to move one unit on the Likert perception scale,
were considered as estimates of the MID. For the bronchodila-
tion data subset, since each participant could contribute more
than one comparison point, mixed regression models were
adjusted to the data in order to account for potential depen-
dency between observations. In the bronchodilation studies,
three outlying observations were identiﬁed using the Cook
distance measure and the DFFITS statistics; they were removed
from the regression analysis. The analyses were done using the
Mixed Procedure of SAS (SAS 9.2, SAS Institute, Cary, North
Carolina, USA).
RESULTS
Characteristics of the two study subgroups are presented in
table 1. Overall, the sample consisted of participants with mild
to severe airﬂow obstruction and varying exercise capacities, as
indicated by the wide range of forced expiratory volume in 1 s
(FEV1) values and performance on the ISWT and the ESWT.
Patients in the pulmonary rehabilitation group were older,
included a higher proportion of women and displayed signiﬁ-
cantly lower FEV1 (litres), forced vital capacity (FVC; litres),
ISWT distance (m) and ESWT distance (m), time (s) and speed
(m/s) compared with patients in the pharmacotherapy group.
Tables 2 and 3 show changes in ESWT time and distance
following the two study interventions and according to
perceived change (3 to +3). After pulmonary rehabilitation,
patient ratings of change correlated signiﬁcantly with the
changes in ESWT time expressed in seconds (r¼0.37, p<0.0001)
and percentage change (r¼0.16, p¼0.06), and with the changes
in ESWT distance expressed in metres (r¼0.35, p<0.0001) and in
percentage change (r¼0.17, p<0.05). Correlations between
subjective and objective changes were stronger with pharma-
cotherapy than with pulmonary rehabilitation. In the bron-
chodilation studies, patient ratings of change correlated
signiﬁcantly with the change in ESWT time expressed in
seconds (r¼0.55, p<0.0001) and percentage change (r¼0.59,
p<0.0001), and with the changes in ESWT distance expressed in
metres (r¼0.53, p<0.0001) and in percentage change (r¼0.59,
p<0.0001).
Using the distribution-based approach (half a SD), pulmonary
rehabilitation data suggested an MID of 186 s or 203 m, which
corresponded to a 136% change in ESWT performance. Our
pharmacotherapy data resulted in an MID of 70 s or 115 m,
which corresponded to a 15% change in ESWT performance.
With the rehabilitation data, obtaining a valid estimation of
the MID using the anchor-based method was not possible
because of the weak correlations between the anchors and the
measured change in ESWT performance. In fact, using the
perception of change as an anchor for the rehabilitation data
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resulted in estimations of the MID with wide CIs that included
zero.
Results of the anchor-based approach to determine the MID
for the pharmacotherapy data show that a 65 s (95% CI 45 to
85) change in the endurance time corresponding to an 85 m
(95% CI 60 to 115) change in walking distance was associated
with minimally important change. When expressed in relative
values, the estimated MID was 13% (95% CI 9% to 17%) for the
ESWT endurance time and 15% (95% CI 10% to 19%) for the
ESWT distance. The anchor-based models resulted in coefﬁcients
of determination (R2 statistics) values of 0.261 and 0.267 for the
absolute and relative value model, respectively.
DISCUSSION
The aim of this study was to determine the MID of change for
the ESWTand to verify whether this threshold would be similar
for two different types of therapeutic interventions. We found
that a change of 65 s (95% CI 45 to 85) or 85 m (95% CI 60 to
115), representing 13e15% of the baseline value, was considered
meaningful in the pharmacotherapy trials. However we could
not conﬁrm this MID estimate with the rehabilitation inter-
vention. These results suggest that the MID determined for one
type of intervention may not necessarily apply to another.
Correlation between ESWT performance and the anchor
(perceived change scale) was sufﬁcient to use regression analysis
for the determination of an MID value in the bronchodilation
studies.25 The distribution- and anchor-based methods also
provided very similar estimates of MID in the bronchodilation
studies. The strong agreement between the two methods of
estimating the MID further conﬁrms the validity and the
robustness of our ﬁndings.
We could not conﬁdently determine an MID estimate in the
rehabilitation studies. We see several explanations for why
the anchor-based method failed to yield a convincing estimate of
the MID in the rehabilitation group compared with the phar-
macotherapy group. First, recall time in the medication studies
was only a few days, but 7 weeks separated the two ESWT
performances in the rehabilitation group. Recall accuracy
decreases as time passes,26 evenmore so in older individuals.27 The
longer recall time combined with older age in the rehabilitation
group might have introduced a recollection error28 that affected
the correlation between subjective and objective change.
Secondly, the one-item question used to evaluate patient
rating of change essentially relies on the fact that a patient’s
internal perception of his health does not change over the course
of the intervention,29 so that the frame of reference of the study
question remains the same. Because pulmonary rehabilitation
has a bigger potential to affect a patient’s perception of his
health than pharmacotherapy,30 the post-treatment state in the
former group was probably more altered when compared with
the medication group. In addition, the longer the time span, the
more likely it is that other health conditions (eg, exacerbations)
may inﬂuence a patient’s present perception29 31 and alter the
validity of the memory recall.
Thirdly, the differences in study design between interventions
may also have had a signiﬁcant impact on the MID calculated
using the perception of global change. The medication arm used
a double-blind, placebo-controlled, crossover study design:
Table 2 Improvements in ESWT time according to perception
of change
Perception
of change
Improvement (s)
Rehabilitation Bronchodilatation
N D time (s) N D time (s)
3.0 0 e 1 335.00
2.0 0 e 6 194.506115.78
1.0 2 144.069.9 12 68.25647.18
0.0 15 24.96294.0 29 2.486101.20
1.0 21 265.76308.2 51 22.716133.65
2.0 46 315.16356.9 31 103.426143.37
3.0 48 484.36374.5 13 90.626120.00
Values are mean6SD.
ESWT, endurance shuttle walk test.
Table 3 Improvements in ESWT distance according to perception
of change
Perception
of change
Improvement (s)
Rehabilitation Bronchodilatation
N D distance (m) N D distance (m)
3.0 0 e 1 460.0
2.0 0 e 6 377.56278.0
1.0 2 96.7641.3 12 87.5652.1
0.0 15 14.76250.2 29 7.96137.7
1.0 21 259.36455.5 51 37.66197.3
2.0 46 276.36312.3 31 140.66192.9
3.0 48 492.76445.3 13 179.26278.1
Values are mean6SD.
ESWT, endurance shuttle walk test.
Table 1 Baseline characteristics of the study group (n¼201)
Pulmonary rehabilitation (N[132) Bronchodilation (N[69) p Value
Males/females, n 75/57 51/18 0.015*
Age, years 68611 (41e86) 6567 (51e80) 0.02
BMI, kg/m2 2766 (15e50) 2765 (18e43) 0.96
FEV1, litres 1.1960.56 (0.41e2.93) 1.3660.47 (0.64e2.46) 0.02
FEV1, % predicted 48622 (9e125) 50612 (24e78) 0.35
FVC, litres 2.3960.88 (1.02e5.25) 3.1060.99 (1.28e6.12) <0.0001
FEV1/FVC, % 50617 (23e105) 44610 (26e65) 0.05
ISWT distance, m 2036129 (20e650) 4836148 (190e790) <0.0001
ESWT
Distance, m 2196200 (0e2000) 6366366 (160e2010) <0.0001
Time, s 2306178 (15e1200) 4846223 (192e1272) <0.0001
Speed (/ms)* 0.8960.31 (0.42e1.67) 1.2460.18 (0.84e1.58) <0.0001
BMI, body mass index; ESWT, endurance shuttle walking test; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; ISWT,
incremental shuttle walking test.
Values are mean6SD (range).
*Two-tailed Fisher test.
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patients could therefore expect improvements, status quo or
deterioration in their ESWT performance. This design might
have had an impact on the expectations of the patients and
might have required them to be more critical in their evaluation
of change. In contrast, patients undergoing pulmonary rehabil-
itation were not subjected to the possibility of sham training.
Hence, they more probably expected and desired improvements
in ESWT performance.
Finally, the level of commitment and personal investment in
the treatment is likely to inﬂuence the magnitude of improve-
ment considered worth obtaining with a given treatment. The
time and effort involved with pulmonary rehabilitation is
greater compared with pharmacotherapy; it is likely that
patients might judge their performance differently because of
greater investment in resources.
Irrespective of the mechanisms involved, the ﬁnding that the
MID may vary according to the nature of the intervention and
baseline performance is important. In clinical practice, the
MID that was found for the 6-MWT during pulmonary
rehabilitation32 was subsequently applied to pharmacotherapy
trials33 and to diseases other than COPD34: the present ﬁnd-
ings certainly question this practice. Investigators should be
careful when applying the MID value obtained in a speciﬁc
clinical context with that in a different clinical situation. We
would suggest that further studies be done to try and deﬁne an
MID estimate for pulmonary rehabilitation using anchors with
sufﬁcient correlation with the improvements in ESWT
performance.
Another important issue is whether a unique absolute MID
value applies throughout the range of baseline ESWTperformance
or whether theMID estimates should be expressed as a fraction of
the baseline values. In the ﬁeld of COPD research, MID values
have usually been reported as ﬁxed values, expressed in the unit of
the instrument.32 35 36 The underlying assumption is that the
MID value is identical across the range of observed scores. In the
ﬁeld of psychophysics, extensive research has been done on this
matter, albeit on less complex constructs than exercise perfor-
mance, and itmay provide important insight. Studies have shown
that the just noticeable difference between two stimuli is
dependent on the intensity of the original stimulus.37e39
To address this possibility, we tested whether a model in
which the changes in ESWT walking performance were
expressed as a percentage of baseline values would be superior to
the absolute value approach. We did not ﬁnd any important
differences in the accuracy of the MID estimation between the
absolute and relative model; this would seem to indicate that
a unique absolute MID values might apply across the range of
ESWT performance.
The concept of MID seeks a patient-centred perspective in the
interpretation of results. However, strictly speaking, we have
deﬁned in the present study a threshold of change in ESWT that
could be perceived either positively or negatively by the patients.
As others,32 we refer to this threshold as the MID. This relates
more to the threshold of perception than a true signiﬁcance of
clinical change.
Despite the fact that they both involve walking, the ESWT
and the 6-MWT have very different designs and properties. As
such, the choice of the test that should be used in a given clinical
or research situation should be based on the speciﬁc question
being asked. The discriminative properties of the 6-MWT have
been established in patients with COPD40e42 and in other
pulmonary diseases.43 The 6-MWT is also easy to administer,
although its methodology should be well standardised to opti-
mise the validity of the results.44 The estimation of the MID
value for the 6-MWT has been the subject of several investiga-
tions.32 45e48 Although the 6-MWT is responsive to rehabilita-
tion,49 its responsiveness to pharmacological interventions may
not be optimal. For example, bronchodilation provides small and
inconsistent improvement in the distance covered during the
6-MWT.50e55 In pulmonary hypertension, pharmacological
interventions also only provide modest improvement in the
6 min walking distance.56 The clinical experience with the
ESWT is not as extensive as with the 6-MWT. To our knowledge,
our study is the ﬁrst to provide an estimation of its MID.
Whether the endurance time during the ESWT is predictive of
important clinical outcomes such as mortality has not been
reported. Despite these limitations, one appealing feature of the
ESWT is its responsiveness to treatment, which has been shown
to be superior to that of the 6-MWT, with both bronchodila-
tion19 and rehabilitation.12 These differences in discriminative
and evaluative properties between both walking tests is in part
related to their design, the main point being that the 6-MWT is
self-paced and the ESWT externally paced. Our current view is
that the 6-MWTwill perform well to quantify exercise tolerance
or to provide prognostic information. In turn, the bulk of
evidence indicates that the ESWT is more responsive to inter-
ventions, such as bronchodilatation and pulmonary rehabilita-
tion, than the 6-MWT and incremental exercise protocols.10 12
Our study further supports the use of the ESWT in clinical trials
evaluating the effectiveness of bronchodilatation treatment by
providing an estimation of the MID, which will facilitate
calculation of sample size and the interpretation of results.
Methodological considerations and potential limitations
A larger sample size for both the pulmonary rehabilitation and
the bronchodilatation groups would have provided additional
statistical power to estimate the MID. Despite the small
difference in the degree of similar airﬂow obstruction between
the two groups, the rehabilitation group had a lower exercise
tolerance at baseline. In the bronchodilatation studies, the MID
estimations were not inﬂuenced by the baseline exercise
capacity, as shown by the similar predictive power of the
absolute and the relative change value regression models. Also,
there was overlap in exercise performance in the two groups.
Based on this discussion, we submit that the failure to estimate
an MID value from the rehabilitation data has more to do with
the nature of the intervention that with a lower exercise toler-
ance found in this group at baseline. In a previous study, we
succeeded in ﬁnding an MID value for the constant workrate
cycling test in a pulmonary rehabilitation context. In this study,
the anchor that was used was the St. George’s Respiratory
Questionnaire57 that is composed of four domains. It would be
of interest to try to evaluate whether a multidimensional anchor
would allow estimation of the MID value for the ESWT with
pulmonary rehabilitation.
Among the various distribution-based approaches to estimate
MID, we selected the half SD approach for its simplicity and
also because it performs reasonably well at identifying the MID
when compared with other, more complicated methods.23 58 It is
however important to acknowledge that there are inconsis-
tencies across the different distribution-based approaches58 and
that they should be viewed as providing preliminary MID esti-
mates until validated anchor-based approach estimates become
available. To increase the conﬁdence of our anchor-based MID
estimate, the data were also analysed using additional regression
models; using the baseline endurance time values as a covariate
in the linear regression model did not signiﬁcantly alter the MID
estimate. We noted that the residuals of the linear regression
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model were not normally distributed; however, no trans-
formations could satisfy the postulates of normality and the
BoxeCox method recommended that we did not transform the
data. To address this potential limitation, the data were trans-
formed to satisfy normality according to a method proposed by
Huber.59 The MID estimate provided by this model (56 s (CI 43
to 70)) fell within the 95% CI of the MID value from the linear
regression model, providing reassurance about the validity of our
ﬁndings.
CONCLUSION
The present study suggests that the nature of the intervention
may affect the patients’ perception of change after treatment.
Our data set suggests that a change in ESWT performance
between 45 and 85 s (or 60e115 m) for a small and large
improvement, respectively, is likely to be perceived by patients,
following a bronchodilatation intervention. We were unable,
however, to estimate with conﬁdence an MID value for the
pulmonary rehabilitation data set, therefore suggesting that an
MID determined for a given intervention might not necessarily
be valid for another intervention. This observation warrants
caution in how the MID concept is applied in interpreting
clinical trials.
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